Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24074971 | 0.86 | GRIA1 (0.52) | GRIA1NPY5RGRIA4ALDH1A1TSHR | |
| SCHEMBL19592332 | 0.82 | GRIA1 (0.52) | GRIA1NPY5RGRIA4ALDH1A1 | |
| SCHEMBL24571561 | 0.81 | GRIA1 (0.52) | GRIA1NPY5RGRIA4ALDH1A1TSHR | |
| SCHEMBL24571852 | 0.80 | GRIA1 (0.50) | GRIA1NPY5RGRIA4ALDH1A1 | |
| SCHEMBL8404635 | 0.80 | GRIA1 (0.50) | GRIA1NPY5RGRIA4ALDH1A1TSHR | |
| SCHEMBL24571558 | 0.79 | GRIA1 (0.48) | GRIA1NPY5RGRIA4ALDH1A1KDM4E | |
| SCHEMBL24571555 | 0.79 | GRIA1 (0.48) | GRIA1NPY5RGRIA4ALDH1A1KDM4E | |
| SCHEMBL13104029 | 0.78 | GRIA1 (0.58) | GRIA1NPY5RGRIA4GAAALDH1A1 | |
| SCHEMBL11706858 | 0.78 | GAA (0.40) | GAAALDH1A1TSHRKDM4EPNMT | |
| SCHEMBL24571575 | 0.77 | GRIA1 (0.52) | GRIA1NPY5RGRIA4ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137910-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137910-A1 | SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE | HIF1AN, VHL, HIF1A | GRIA1 3535/4885NPY5R 4142/4885GRIA4 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.